Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: A report of two cases successfully treated without hysterectomy

Gynecologic Oncology

Volumn 94, Issue 3, 2004, Pages 832-834

  Burnett, Alexander F ^a,d   Bahador, Afshin ^b   Amezcua, Charles ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anastrazole; Hysterectomy; Medroxyprogesterone acetate

Indexed keywords

ANASTROZOLE; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; FERTILITY; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; HYSTERECTOMY; OBESITY; PREMENOPAUSE; PRIORITY JOURNAL; REPRODUCTION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NITRILES; OBESITY; TRIAZOLES;

EID: 4444346107     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.06.004     Document Type: Article

References (11)

1. Morrow C.P., Curtin J.P. Synopsis of gynecologic oncology. fifth ed.:1998;Churchill Livingstone, New York
2. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D, Manetta A., et al. Oral medroxyprogesteone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 17:1999;1736-1744
3. Carcangiu M.L., Chambers J.T., Voynick I.M., Pirro M., Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am. J. Clin. Pathol. 94(3):1990;247-254
4. Gotlieb W.H., Beiner M.E., Shalmon B., Korach Y., Segal Y., Zmira N., et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstetric. Gynecol. 102(4):2003;718-725
5. Wang C.B., Wang C.H., Huang H.F., Hsueh S., Chou H.H., Soong Y.K., et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 94(8):2002;2192-2198
6. Imai M., Jobo T., Sato R., Kawaguchi M., Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus - Usefulness and limitations. Eur. J. Gynaecol. Oncol. 22(3):2001;217-220
7. Lowe M.P., Cooper B.C., Sood A.K., Davis W.A., Syrop C.H., Sorosky J.I. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol. Oncol. 91(3):2003;569-572
8. Dowsett M., Lonning P.E. Anastrozole - A new generation in aromatase inhibition: clinical pharmacology. Oncology. 54(Suppl. 2):1997;11-14
9. Buzdar A.U., Jones S.E., Vogel C.L., Wolter J., Plourde P., Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group Cancer. 79(4):1997;730-739
10. Buzdar A.U. ATAC trialists' group Arimidex (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast carcinoma - Efficacy overview. J. Steroid Biochem. Molec. Biol. 86(3-5):2003;399-403
11. Rose P.G., Brunetto V.L., VanLe L., Bell J., Walker J.L., Lee R.B. A phase II trial of Anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 78:2000;212-216